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Dear Editor,
At the beginning of the third millennium, Hepatitis 
C virus (HCV) infection continues to be a major health 
hazard, with 170 million chronically infected people 
worldwide (1). Recent research has found that the 
prevalence of HCV infection in Iran is 1% and 0.1% in males 
and females, respectively (2). Although a combination 
of pegylated interferon (PEG-IFN) and ribavirin (RBV) 
has been established as a standard anti-HCV therapy, 
treatment responses vary. Numerous factors, including 
gender, age, HCV RNA level prior to treatment, liver 
cirrhosis, and HCV genotypes have been determined to 
contribute to this discrepancy (1). In addition, a number 
of recently published, genome-wide association studies 
(GWAS) have shown that polymorphisms within the IL28B 
locus result in differences between patients’ responses 
to anti-HCV treatment (3-6). In this regard, rs8099917 
(8 kb upstream of the IL28B gene) and rs12979860 (3 
kb upstream of the IL28B gene) have been identified as 
relevant single nucleotide polymorphisms (SNPs) that 
significantly impact treatment response to HCV infection 
(7). Although both SNPs are known to be independent 
predictors of response to anti-HCV therapy, a recent, 
extensive meta-analysis has reported that rs12979860 
is more closely related to treatment responses (8). The 
prevalence of these SNPs and the rate of sustained viral 
response (SVR) have been found to vary across Caucasian, 
African American, and Japanese ethnicities (1). Based 
on these important findings, this preliminary report 
presents data on IL28B SNP (rs12979860) in a group of 
Iranian HCV-infected patients. To our knowledge, this is 
the first such report published from this region, and we 
hope that the results will stimulate extensive research.
In this study, 68 HCV-infected patients were referred 
to and enrolled in 2009 at the Tehran Hepatitis Center, a 
primary referral hepatitis center in Iran. Of these patients, 
46 (67.6%) were male and 22 (32.4%) were female, with a 
Mean ± SD age of 44.57 ± 13.67 years (ranging from 10 to 
75 years). Whole blood (2-ml samples) in EDTA tubes was 
collected from these patients for genotyping analysis. 
DNA was extracted from 200 µl of whole blood using a 
pure gene Blood Core C kit (Qiagen, Hilden, Germany) 
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according to the manufacturer’s manual. The quality 
and the purity of extracted DNA were measured with 
a NanoDrop 1000 spectrophotometer. Real-time PCR 
was performed on IL28B SNP (rs12979860) using Roche 
LightCycler 480 II according to Ge, et al.'s publication (3). 
The genotyping results were reported as C/C, C/T, and T/T. 
The SNP genotyping results for the study group, as shown 
in Table 1, showed C/C in 52.9% (No.= 36), C/T in 39.7% (No. 
= 27) and T/T in 7.3% of patients (No. = 5). Table 2 shows 
HCV genotypes of the study group according to IL28B 
SNP genotyping. The table shows that C allele, which is 
known as the protective allele, was present in more than 
90% of the HCV-infected patients in this Iranian sample. 
This is in accordance with what has been reported in a 
previous study among healthy individuals, in which the 
C allele was reported to be more frequent, especially 
in East Asia. In that study, conducted by Thomas, et al. 
the authors have suggested that IL28B is under active 
selection, especially in the abovementioned geographic 
region (1). Accordingly, our results support this 
hypothesis in Iran, a country located in southwestern 
Asia. Moreover, we believe that our findings can explain 
previous observations demonstrating the higher rates of 
SVR among Iranian HCV-infected patients in comparison 
with similar patients from other countries (9). As 
previously described, Iranian HCV-infected patients 
with genotype 1 responded better than expected to 
anti-HCV therapy, and some hypotheses were made to 
justify this observation. The high prevalence of C/C and 
C/T genotypes of rs12979860 compared with the low 
prevalence of T/T among this sample of HCV-infected 
patients is one possible reason for the higher SVR rate. To 
draw a more robust conclusion in this regard, a cohort 
study involving a large number of HCV-infected patients 
is under way in our center. The study is investigating the 
prevalence of both rs12979860 and rs8099917 and their 
probable influences on the SVR rate among Iranian HCV-
infected patients, and the results will be published soon.
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HCV Genotype Total
1 3 non-typable 3a and 1a 2 4
IL28B
CC
CT
TT
Total
21
21
2
44
9
3
1
13
2
0
0
2
1
1
0
2
1
0
0
1
0
1
0
1
34
26
3
63
Table2. HCV genotypes of the study group according to SNP genotyping
Gender
Male [No. (%)] Female [No. (%)] 
IL28
CC
CT
TT
Total
24 (66.7%)
19 (70.4%)
3 (60%)
46
12 (33.3%)
8 (29.6%)
2 (40%)
22
36
27
5
68
Table1. SNP genotyping results of the study group